Pharma exports to China

Pharmaceutical exports: Window of opportunity

Print edition :
India’s pharmaceutical exports to China have enormous growth potential and could play a vital role in reducing the bilateral trade deficit.

DURING his Indian visit in October, Chinese President Xi Jinping said that his country invited investments from Indian pharmaceutical companies, bringing into the spotlight the size of India’s exports to China and the potential of the Chinese market in general.

According to statistics from the Department of Commerce, India's pharmaceutical exports to China have been growing at a brisk pace in recent years but the country still remains far below than several other traditional markets.

The total value of exports touched $16,785 million in the 2016-17 fiscal and rose 2.95 per cent to $17,281 million in 2017-18, before growing 10.72 per cent to $19,134 million in 2018-19.

In 2018-19, the United States was the top export destination, accounting for a lion’s share of 30.42 per cent of export revenue ($5,820.41 million). It was followed by the United Kingdom ($630.17 million), South Africa ($619.08 million), Russia ($485.55 million) and Brazil ($452.05 million).

China ranked 17th, accounting for $230.19 million in 2018-19. However, it was a 14.83 per cent growth from the previous year, when exports were worth $200.46 million.

According to, the U.S. exported $3.02 billion worth of pharmaceutical preparations to China in 2018, compared with $2.69 billion in 2017 and $2.17 billion in 2016.

A report by the U.S. Department of Commerce in 2016 said that China was the second largest pharmaceutical market in the world, “forecasted to grow from $108 billion in 2015 to $167 billion by 2020”.

The report also said that total public and private healthcare expenditure in China, which reached $640 billion in 2015, was expected to nearly double to $1.1 trillion by 2020.

“Generics dominate with a hefty 64 per cent of total sales,” it said, adding that the Chinese generics market was projected to reach $80 billion in by 2017.

A letter from the Editor

Dear reader,

The COVID-19-induced lockdown and the absolute necessity for human beings to maintain a physical distance from one another in order to contain the pandemic has changed our lives in unimaginable ways. The print medium all over the world is no exception.

As the distribution of printed copies is unlikely to resume any time soon, Frontline will come to you only through the digital platform until the return of normality. The resources needed to keep up the good work that Frontline has been doing for the past 35 years and more are immense. It is a long journey indeed. Readers who have been part of this journey are our source of strength.

Subscribing to the online edition, I am confident, will make it mutually beneficial.


R. Vijaya Sankar

Editor, Frontline

Support Quality Journalism


This article is closed for comments.
Please Email the Editor